These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 15583115

  • 1. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [Abstract] [Full Text] [Related]

  • 2. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [Abstract] [Full Text] [Related]

  • 3. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM.
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF.
    J Clin Psychiatry; 1995 Dec; 56 Suppl 6():30-6. PubMed ID: 7649971
    [Abstract] [Full Text] [Related]

  • 7. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
    Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR.
    Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 9. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT, Isaac MB, Gallo F, Tournoux A.
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [Abstract] [Full Text] [Related]

  • 10. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 11. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD, Bodkin JA.
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 13. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 14. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR.
    J Clin Psychiatry; 1996 Aug; 57 Suppl 2():15-8. PubMed ID: 8626358
    [Abstract] [Full Text] [Related]

  • 15. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 17. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Sep; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 19. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.